ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,064.20
0.91%
Dow Jones
38,225.66
0.00%
US Dollar vs MXN
16.9323
-0.24%
Brent Oil
84.155
0.63%
Bitcoin
59,107.91
-0.02%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Aquestive Therapeutics Inc (AQST)

  7. Aquestive Therapeutics Inc (AQST) Noticias

AQST Aquestive Therapeutics Inc

3.28
0.00 (0.00%)
Pre Mercado
Última actualización: 06:44:37
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Aquestive Therapeutics Inc AQST NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.00 0.00% 3.28 06:44:37
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
3.28
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
29/4/202406:00GLOBEAquestive Therapeutics Receives U.S. FDA Approval and Market..
25/4/202407:00GLOBEAquestive Therapeutics to Report First Quarter 2024..
12/4/202415:01GLOBEAquestive Therapeutics to Present Crossover Study Data for..
01/4/202407:00GLOBEAquestive Therapeutics Strengthens Board of Directors with..
25/3/202407:00GLOBEAquestive Therapeutics Announces Closing of Underwritten..
19/3/202420:49GLOBEAquestive Therapeutics Announces Pricing of $75 Million..
19/3/202415:01GLOBEAquestive Therapeutics Announces Proposed Public Offering of..
14/3/202416:23GLOBEAquestive Therapeutics Announces Pivotal Study for Anaphylm™..
11/3/202409:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/3/202409:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/3/202409:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/3/202409:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/3/202409:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/3/202409:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/3/202409:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/3/202415:14EDGAR2Form 144 - Report of proposed sale of securities
05/3/202416:12EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
05/3/202416:09EDGAR2Form 8-K - Current report
05/3/202416:05GLOBEAquestive Therapeutics Reports Full Year 2023 Financial..
21/2/202407:00GLOBEAquestive Therapeutics to Report Fourth Quarter 2023..
15/2/202407:00GLOBEAquestive Therapeutics to Present Anaphylm™ (epinephrine)..
14/2/202414:24EDGAR2Form SC 13G - Statement of acquisition of beneficial..
12/2/202416:02EDGAR2Form S-8 - Securities to be offered to employees in employee..
30/1/202407:00GLOBEAquestive Therapeutics to Participate in Oppenheimer 34th..
08/12/202309:46EDGAR2Form 8-K - Current report
05/12/202307:51EDGAR2Form 8-K - Current report
05/12/202307:00GLOBEAquestive Therapeutics Doses First Patient in Phase 3..
10/11/202307:00GLOBEAquestive Therapeutics to Present Positive Data from..
08/11/202316:04EDGAR2Form 8-K - Current report
06/11/202316:22EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/11/202316:20EDGAR2Form 8-K - Current report
06/11/202315:37GLOBEAquestive Therapeutics Reports Third Quarter 2023 Financial..
02/11/202307:45EDGAR2Form 8-K - Current report
02/11/202307:00GLOBEAquestive Therapeutics Completes $45 Million Debt..
31/10/202307:00GLOBEAquestive Therapeutics to Report Third Quarter 2023..
10/10/202311:04EDGAR2Form 8-K - Current report
09/10/202307:00GLOBEAquestive Therapeutics Provides Business Update
02/10/202315:18EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
01/10/202323:15EDGAR2Form EFFECT - Notice of Effectiveness
20/9/202315:39EDGAR2Form 8-K - Current report
20/9/202309:57DJNAquestive Therapeutics Shares Rise 12% on Anaphylm Trial..
20/9/202308:04GLOBEAquestive Therapeutics Reaffirms Timeline and Pathway for..
11/9/202307:00GLOBEAquestive Therapeutics Receives FDA Acceptance of New Drug..
23/8/202307:00GLOBEAquestive Therapeutics to Participate in Two Upcoming..
11/8/202312:14EDGAR2Form 8-K - Current report
09/8/202316:22EDGAR2Form S-8 - Securities to be offered to employees in employee..
09/8/202315:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/8/202315:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/8/202315:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/8/202315:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Su Consulta Reciente

NASDAQ
AQST
Aquestive Therapeutics
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados